{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T03:59:29Z","timestamp":1778903969390,"version":"3.51.4"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2022,2,3]],"date-time":"2022-02-03T00:00:00Z","timestamp":1643846400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,2,3]],"date-time":"2022-02-03T00:00:00Z","timestamp":1643846400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"National Science and Technology Major Project of China","award":["2016ZX09101094"],"award-info":[{"award-number":["2016ZX09101094"]}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82072837"],"award-info":[{"award-number":["82072837"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Transl Oncol"],"published-print":{"date-parts":[[2022,7]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Purpose<\/jats:title>\n                <jats:p>Translocation renal cell carcinoma (tRCC) is a subtype that occurs predominantly in children and young individuals. Metastatic tRCC occurring in young patients is more aggressive than that occurring in older patients, and there are still no effective therapies. Organoids can mimic original tissues and be assessed by high-throughput screening (HTS). We aimed to utilize patient-derived organoids and HTS to screen drugs that can be repurposed for metastatic tRCC with PRCC-TFE3 fusion.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Tumor tissues were obtained from treatment-na\u00efve metastatic tRCC patients who underwent surgery. Histopathology and fluorescence in situ hybridization (FISH) confirmed the tRCC. Organoids derived from the dissected tissues were cultured and verified by FISH and RNA-seq. HTS was performed to seek promising drugs, and potential mechanisms were explored by RNA-seq and cell-based studies.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>We successfully established a metastatic tRCC organoid with PRCC-TFE3 fusion, a common fusion subtype, and its characteristics were verified by histopathology, FISH, and RNA-seq. An HTS assay was developed, and the robustness was confirmed. A compound library of 1816 drugs was screened. Eventually, axitinib, crizotinib, and JQ-1 were selected for further validation and were found to induce cell cycle arrest and apoptosis. RNA-seq analyses of posttreatment organoids indicated that crizotinib induced significant changes in autophagy-related genes, consistent with the potential pathogenesis of tRCC.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>We established and validated organoids derived from tissues dissected from a patient with metastatic tRCC with PRCC-TFE3 fusion and achieved the HTS process for the first time. Crizotinib might be a targeted therapy worthy of exploration in the clinic for metastatic tRCC with PRCC-TFE3 fusion. Such organoid and HTS assays may represent a promising model system in translational research assisting in the development of clinical strategies.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s12094-021-02774-8","type":"journal-article","created":{"date-parts":[[2022,2,3]],"date-time":"2022-02-03T18:08:38Z","timestamp":1643911718000},"page":"1333-1346","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Phenotypical screening on metastatic PRCC-TFE3 fusion translocation renal cell carcinoma organoids reveals potential therapeutic agents"],"prefix":"10.1007","volume":"24","author":[{"given":"Chuanzhen","family":"Cao","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaomei","family":"Lan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bingqing","family":"Shang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Weixing","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lei","family":"Guo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shan","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xingang","family":"Bi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aiping","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhijian","family":"Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1148-2442","authenticated-orcid":false,"given":"Jianzhong","family":"Shou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,2,3]]},"reference":[{"issue":"4","key":"2774_CR1","doi-asserted-by":"publisher","first-page":"1170","DOI":"10.1158\/1078-0432.CCR-08-1183","volume":"15","author":"Y Komai","year":"2009","unstructured":"Komai Y, Fujiwara M, Fujii Y, Mukai H, Yonese J, Kawakami S, et al. Adult Xp11 translocation renal cell carcinoma diagnosed by cytogenetics and immunohistochemistry. Clin Cancer Res: Off J Am Assoc Cancer Res. 2009;15(4):1170\u20136.","journal-title":"Clin Cancer Res: Off J Am Assoc Cancer Res"},{"key":"2774_CR2","doi-asserted-by":"publisher","first-page":"21677","DOI":"10.1038\/srep21677","volume":"6","author":"Y Qu","year":"2016","unstructured":"Qu Y, Gu C, Wang H, Chang K, Yang X, Zhou X, et al. Diagnosis of adults Xp11.2 translocation renal cell carcinoma by immunohistochemistry and FISH assays: clinicopathological data from ethnic Chinese population. Sci Rep. 2016;6:21677.","journal-title":"Sci Rep"},{"issue":"8","key":"2774_CR3","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1038\/nrurol.2014.162","volume":"11","author":"EC Kauffman","year":"2014","unstructured":"Kauffman EC, Ricketts CJ, Rais-Bahrami S, Yang Y, Merino MJ, Bottaro DP, et al. Molecular genetics and cellular features of TFE3 and TFEB fusion kidney cancers. Nat Rev Urol. 2014;11(8):465\u201375.","journal-title":"Nat Rev Urol"},{"issue":"9","key":"2774_CR4","doi-asserted-by":"publisher","first-page":"1346","DOI":"10.1038\/s41379-018-0051-5","volume":"31","author":"XT Wang","year":"2018","unstructured":"Wang XT, Xia QY, Ye SB, Wang X, Li R, Fang R, et al. RNA sequencing of Xp11 translocation-associated cancers reveals novel gene fusions and distinctive clinicopathologic correlations. Modern pathol\u202f: Off United States Can Aca Pathol, Inc. 2018;31(9):1346\u201360.","journal-title":"Modern pathol : Off United States Can Aca Pathol, Inc"},{"issue":"12","key":"2774_CR5","doi-asserted-by":"publisher","first-page":"1637","DOI":"10.1158\/1541-7786.MCR-17-0320","volume":"15","author":"L Slade","year":"2017","unstructured":"Slade L, Pulinilkunnil T. The MiTF\/TFE family of transcription factors: master regulators of organelle signaling, metabolism, and stress adaptation. Mol Cancer Res: MCR. 2017;15(12):1637\u201343.","journal-title":"Mol Cancer Res: MCR"},{"issue":"5","key":"2774_CR6","doi-asserted-by":"publisher","first-page":"e819","DOI":"10.1016\/j.clgc.2017.04.015","volume":"15","author":"MS Choo","year":"2017","unstructured":"Choo MS, Jeong CW, Song C, Jeon HG, Seo SI, Hong SK, et al. Clinicopathologic characteristics and prognosis of Xp11.2 translocation renal cell carcinoma: multicenter, propensity score matching analysis. Clin Genitourin Cancer. 2017;15(5):e819\u201325.","journal-title":"Clin Genitourin Cancer"},{"issue":"2","key":"2774_CR7","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1007\/s00345-008-0262-3","volume":"26","author":"JG Garcia","year":"2008","unstructured":"Garcia JG, Picken MM, Flanigan RC. The importance of histology and cytogenetics in decision making for renal cell carcinoma. World J Urol. 2008;26(2):155\u201360.","journal-title":"World J Urol"},{"issue":"6","key":"2774_CR8","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1177\/1066896910375565","volume":"18","author":"R Qiu","year":"2010","unstructured":"Qiu R, Bing G, Zhou XJ. Xp11.2 translocation renal cell carcinomas have a poorer prognosis than non-Xp11.2 translocation carcinomas in children and young adults: a meta-analysis. Int J Surg Pathol. 2010;18(6):458\u201364.","journal-title":"Int J Surg Pathol"},{"issue":"3","key":"2774_CR9","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1038\/s41419-019-1453-0","volume":"10","author":"L Grassi","year":"2019","unstructured":"Grassi L, Alfonsi R, Francescangeli F, Signore M, De Angelis ML, Addario A, et al. Organoids as a new model for improving regenerative medicine and cancer personalized therapy in renal diseases. Cell Death Dis. 2019;10(3):201.","journal-title":"Cell Death Dis"},{"issue":"1","key":"2774_CR10","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1038\/s41467-020-14700-7","volume":"11","author":"A Fendler","year":"2020","unstructured":"Fendler A, Bauer D, Busch J, Jung K, Wulf-Goldenberg A, Kunz S, et al. Inhibiting WNT and NOTCH in renal cancer stem cells and the implications for human patients. Nat Commun. 2020;11(1):929.","journal-title":"Nat Commun"},{"issue":"4","key":"2774_CR11","doi-asserted-by":"publisher","first-page":"1066","DOI":"10.1053\/j.gastro.2017.10.043","volume":"154","author":"A Lampis","year":"2018","unstructured":"Lampis A, Carotenuto P, Vlachogiannis G, Cascione L, Hedayat S, Burke R, et al. MIR21 drives resistance to heat shock protein 90 inhibition in cholangiocarcinoma. Gastroenterology. 2018;154(4):1066-79.e5.","journal-title":"Gastroenterology"},{"issue":"1","key":"2774_CR12","doi-asserted-by":"publisher","first-page":"2404","DOI":"10.1038\/s41467-018-04495-z","volume":"9","author":"L Puca","year":"2018","unstructured":"Puca L, Bareja R, Prandi D, Shaw R, Benelli M, Karthaus WR, et al. Patient derived organoids to model rare prostate cancer phenotypes. Nat Commun. 2018;9(1):2404.","journal-title":"Nat Commun"},{"issue":"6","key":"2774_CR13","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1097\/PAS.0b013e31827e17cb","volume":"37","author":"Q Rao","year":"2013","unstructured":"Rao Q, Williamson SR, Zhang S, Eble JN, Grignon DJ, Wang M, et al. TFE3 break-apart FISH has a higher sensitivity for Xp11.2 translocation-associated renal cell carcinoma compared with TFE3 or cathepsin K immunohistochemical staining alone: expanding the morphologic spectrum. Am J Surg Pathol. 2013;37(6):804\u201315.","journal-title":"Am J Surg Pathol"},{"key":"2774_CR14","first-page":"81","volume":"8","author":"A Frick","year":"2015","unstructured":"Frick A, Fedoriw Y, Richards K, Damania B, Parks B, Suzuki O, et al. Immune cell-based screening assay for response to anticancer agents: applications in pharmacogenomics. Pharmgenomics Pers Med. 2015;8:81\u201398.","journal-title":"Pharmgenomics Pers Med"},{"key":"2774_CR15","doi-asserted-by":"publisher","first-page":"103232","DOI":"10.1016\/j.bioorg.2019.103232","volume":"92","author":"S Hu","year":"2019","unstructured":"Hu S, Zhao Z, Yan H. Discovery and optimization of 5,7-dihydro-6H-pyrrolo[2,3-d]pyrimidin-6-one derivatives as mTORC1\/mTORC2 dual inhibitors. Bioorg Chem. 2019;92:103232.","journal-title":"Bioorg Chem"},{"issue":"7","key":"2774_CR16","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1177\/1087057112443987","volume":"17","author":"KF Sachsenmeier","year":"2012","unstructured":"Sachsenmeier KF, Hay C, Brand E, Clarke L, Rosenthal K, Guillard S, et al. Development of a novel ectonucleotidase assay suitable for high-throughput screening. J Biomol Screen. 2012;17(7):993\u20138.","journal-title":"J Biomol Screen"},{"key":"2774_CR17","doi-asserted-by":"publisher","first-page":"2404","DOI":"10.1038\/s41467-018-04495-z","volume":"9","author":"L Puca","year":"2018","unstructured":"Puca L, Bareja R, Prandi D, Shaw R, Benelli M, Karthaus WR, et al. Patient derived organoids to model rare prostate cancer phenotypes. (2041\u20131723 (Electronic)). Nat Commun. 2018;9:2404.","journal-title":"Nat Commun"},{"issue":"2","key":"2774_CR18","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1177\/108705719900400206","volume":"4","author":"JH Zhang","year":"1999","unstructured":"Zhang JH, Chung TD, Oldenburg KR. A simple statistical parameter for use in evaluation and validation of high throughput screening assays. J Biomol Screen. 1999;4(2):67\u201373.","journal-title":"J Biomol Screen"},{"issue":"5","key":"2774_CR19","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1038\/sj.bjp.0706873","volume":"149","author":"R De La Fuente","year":"2006","unstructured":"De La Fuente R, Sonawane ND, Arumainayagam D, Verkman AS. Small molecules with antimicrobial activity against E. coli and P. aeruginosa identified by high-throughput screening. Br J Pharmacol. 2006;149(5):551\u20139.","journal-title":"Br J Pharmacol"},{"issue":"6","key":"2774_CR20","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1177\/24725552211008854","volume":"26","author":"MD Scholle","year":"2021","unstructured":"Scholle MD, Liu C, Deval J, Gurard-Levin ZA. Label-free screening of SARS-CoV-2 NSP14 exonuclease activity using SAMDI mass spectrometry. SLAS Discov\u202f: Adv Life Sci R & D. 2021;26(6):766\u201374.","journal-title":"SLAS Discov : Adv Life Sci R & D"},{"issue":"5","key":"2774_CR21","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1177\/1087057108317145","volume":"13","author":"XD Zhang","year":"2008","unstructured":"Zhang XD, Espeseth AS, Johnson EN, Chin J, Gates A, Mitnaul LJ, et al. Integrating experimental and analytic approaches to improve data quality in genome-wide RNAi screens. J Biomol Screen. 2008;13(5):378\u201389.","journal-title":"J Biomol Screen"},{"issue":"2","key":"2774_CR22","doi-asserted-by":"publisher","first-page":"2231","DOI":"10.1002\/jcb.26385","volume":"119","author":"Y Shi","year":"2018","unstructured":"Shi Y, Liu X, Fredimoses M, Song M, Chen H, Liu K, et al. FGFR2 regulation by picrasidine Q inhibits the cell growth and induces apoptosis in esophageal squamous cell carcinoma. J Cell Biochem. 2018;119(2):2231\u20139.","journal-title":"J Cell Biochem"},{"issue":"31","key":"2774_CR23","doi-asserted-by":"publisher","first-page":"51675","DOI":"10.18632\/oncotarget.18386","volume":"8","author":"RD Schroeder","year":"2017","unstructured":"Schroeder RD, Choi W, Hong DS, McConkey DJ. Autophagy is required for crizotinib-induced apoptosis in MET-amplified gastric cancer cells. Oncotarget. 2017;8(31):51675\u201387.","journal-title":"Oncotarget"},{"issue":"4","key":"2774_CR24","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1016\/j.molcel.2017.04.027","volume":"66","author":"JI Sakamaki","year":"2017","unstructured":"Sakamaki JI, Wilkinson S, Hahn M, Tasdemir N, O\u2019Prey J, Clark W, et al. Bromodomain protein BRD4 is a transcriptional repressor of autophagy and lysosomal function. Mol Cell. 2017;66(4):517-32.e9.","journal-title":"Mol Cell"},{"issue":"6","key":"2774_CR25","doi-asserted-by":"publisher","first-page":"e243058","DOI":"10.1136\/bcr-2021-243058","volume":"14","author":"C Solano","year":"2021","unstructured":"Solano C, Thapa S, Chisti MM. Adult Xp11.2 translocation renal cell carcinoma managed effectively with pazopanib. BMJ Case Rep. 2021;14(6):e243058.","journal-title":"BMJ Case Rep"},{"issue":"12","key":"2774_CR26","doi-asserted-by":"publisher","first-page":"1424","DOI":"10.1038\/nm.4438","volume":"23","author":"L Broutier","year":"2017","unstructured":"Broutier L, Mastrogiovanni G, Verstegen MM, Francies HE, Gavarr\u00f3 LM, Bradshaw CR, et al. Human primary liver cancer-derived organoid cultures for disease modeling and drug screening. Nat Med. 2017;23(12):1424\u201335.","journal-title":"Nat Med"},{"issue":"8","key":"2774_CR27","doi-asserted-by":"publisher","first-page":"1240","DOI":"10.1007\/s12094-019-02276-8","volume":"22","author":"HD Liu","year":"2020","unstructured":"Liu HD, Xia BR, Jin MZ, Lou G. Organoid of ovarian cancer: genomic analysis and drug screening. Clin Transl Oncol: Off Publ Fed Spanish Oncol Soc Natl Cancer Inst Mexico. 2020;22(8):1240\u201351.","journal-title":"Clin Transl Oncol: Off Publ Fed Spanish Oncol Soc Natl Cancer Inst Mexico"},{"issue":"6378","key":"2774_CR28","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1126\/science.aao2774","volume":"359","author":"G Vlachogiannis","year":"2018","unstructured":"Vlachogiannis G, Hedayat S, Vatsiou A, Jamin Y, Fern\u00e1ndez-Mateos J, Khan K, et al. Patient-derived organoids model treatment response of metastatic gastrointestinal cancers. Science (New York, NY). 2018;359(6378):920\u20136.","journal-title":"Science (New York, NY)"},{"issue":"6","key":"2774_CR29","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1016\/j.stem.2018.04.022","volume":"22","author":"SM Czerniecki","year":"2018","unstructured":"Czerniecki SM, Cruz NM, Harder JL, Menon R, Annis J, Otto EA, et al. High-throughput screening enhances kidney organoid differentiation from human pluripotent stem cells and enables automated multidimensional phenotyping. Cell Stem Cell. 2018;22(6):929-40.e4.","journal-title":"Cell Stem Cell"},{"issue":"5","key":"2774_CR30","doi-asserted-by":"publisher","first-page":"e997","DOI":"10.1016\/j.clgc.2018.05.011","volume":"16","author":"I Park","year":"2018","unstructured":"Park I, Lee SH, Lee JL. A multicenter phase II trial of axitinib in patients with recurrent or metastatic non-clear-cell renal cell carcinoma who had failed prior treatment with temsirolimus. Clin Genitourin Cancer. 2018;16(5):e997\u20131002.","journal-title":"Clin Genitourin Cancer"},{"issue":"12","key":"2774_CR31","first-page":"1477","volume":"11","author":"SJ Rodig","year":"2010","unstructured":"Rodig SJ, Shapiro GI. Crizotinib, a small-molecule dual inhibitor of the c-Met and ALK receptor tyrosine kinases. Curr Opin Investig Drugs. 2010;11(12):1477\u201390.","journal-title":"Curr Opin Investig Drugs"},{"issue":"23","key":"2774_CR32","doi-asserted-by":"publisher","first-page":"4899","DOI":"10.1091\/mbc.e09-05-0380","volume":"20","author":"A Dey","year":"2009","unstructured":"Dey A, Nishiyama A, Karpova T, McNally J, Ozato K. Brd4 marks select genes on mitotic chromatin and directs postmitotic transcription. Mol Biol Cell. 2009;20(23):4899\u2013909.","journal-title":"Mol Biol Cell"},{"issue":"5","key":"2774_CR33","doi-asserted-by":"publisher","first-page":"E420","DOI":"10.1073\/pnas.1424576112","volume":"112","author":"D Ploper","year":"2015","unstructured":"Ploper D, Taelman VF, Robert L, Perez BS, Titz B, Chen HW, et al. MITF drives endolysosomal biogenesis and potentiates Wnt signaling in melanoma cells. Proc Natl Acad Sci USA. 2015;112(5):E420\u20139.","journal-title":"Proc Natl Acad Sci USA"},{"key":"2774_CR34","doi-asserted-by":"publisher","first-page":"117341","DOI":"10.1016\/j.lfs.2020.117341","volume":"244","author":"A Bahrami","year":"2020","unstructured":"Bahrami A, Bianconi V, Pirro M, Orafai HM, Sahebkar A. The role of TFEB in tumor cell autophagy: diagnostic and therapeutic opportunities. Life Sci. 2020;244:117341.","journal-title":"Life Sci"},{"issue":"1","key":"2774_CR35","doi-asserted-by":"publisher","first-page":"5262","DOI":"10.1038\/s41467-021-25618-z","volume":"12","author":"G Sun","year":"2021","unstructured":"Sun G, Chen J, Liang J, Yin X, Zhang M, Yao J, et al. Integrated exome and RNA sequencing of TFE3-translocation renal cell carcinoma. Nat Commun. 2021;12(1):5262.","journal-title":"Nat Commun"},{"key":"2774_CR36","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1186\/s13046-015-0228-4","volume":"34","author":"F Megiorni","year":"2015","unstructured":"Megiorni F, McDowell HP, Camero S, Mannarino O, Ceccarelli S, Paiano M, et al. Crizotinib-induced antitumour activity in human alveolar rhabdomyosarcoma cells is not solely dependent on ALK and MET inhibition. J Exp Clin Cancer Res. 2015;34:112.","journal-title":"J Exp Clin Cancer Res"},{"issue":"10","key":"2774_CR37","doi-asserted-by":"publisher","first-page":"2517","DOI":"10.3390\/cells10102517","volume":"10","author":"E Espinos","year":"2021","unstructured":"Espinos E, Lai R, Giuriato S. The dual role of autophagy in crizotinib-treated ALK (+) ALCL: from the lymphoma cells drug resistance to their demise. Cells. 2021;10(10):2517.","journal-title":"Cells"}],"container-title":["Clinical and Translational Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-021-02774-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12094-021-02774-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-021-02774-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,13]],"date-time":"2022-06-13T16:28:09Z","timestamp":1655137689000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12094-021-02774-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,3]]},"references-count":37,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2022,7]]}},"alternative-id":["2774"],"URL":"https:\/\/doi.org\/10.1007\/s12094-021-02774-8","relation":{},"ISSN":["1699-3055"],"issn-type":[{"value":"1699-3055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,2,3]]},"assertion":[{"value":"30 September 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 December 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 February 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have declared no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The research study was reviewed and approved by the Domain-Specific Review Board, Cancer Hospital Chinese Academy of Medical Sciences (approval number: 20\/246-2442, approval date: 2020-9-30).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Written informed consents were obtained and patient details were anonymized before analysis.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Patient consent"}}]}}